Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.41 |
| ▸ | EP300 | Q09472 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | FPR1 | P21462 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631458 | 0.97 | F10 (0.42) | F10EP300CNR1MAPTFPR1 | |
| SCHEMBL5632127 | 0.87 | F10 (0.49) | F10EP300CNR1MAPTFPR2 | |
| SCHEMBL5631599 | 0.87 | F10 (0.49) | F10EP300CNR1MAPTFPR2 | |
| SCHEMBL5631637 | 0.85 | CYP1A2 (0.41) | F10EP300MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5631123 | 0.84 | F10 (0.47) | F10EP300CNR1MAPTFPR2 | |
| SCHEMBL5630997 | 0.84 | F10 (0.47) | F10EP300CNR1MAPTFPR2 | |
| SCHEMBL5631202 | 0.83 | CYP1A2 (0.39) | F10EP300MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5631765 | 0.83 | CYP1A2 (0.39) | F10EP300MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5631461 | 0.81 | F10 (0.61) | F10CNR1MAPTFPR2ALDH1A1 | |
| SCHEMBL8265403 | 0.80 | F10 (0.42) | F10EP300CNR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183277-B2 | Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants | MERCK PATENT GMBH (DE) | 2007-02-27 | — | — | US | claimed |
| US-20050171154-A1 | Carboxylic acid amides | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| US-7183277-B2 | Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants | MERCK PATENT GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20050171154-A1 | Carboxylic acid amides | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171154-A1 | Carboxylic acid amides | F11, F12, F2 | F10 4/4885EP300 984/4885CNR1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.